Therapeutic Drug Monitoring of Immunosuppressant Drug

1
Therapeutic Drug Monitoring of Immunosuppressant
Drug

• Todd K Fox
• Clinical Pharmacist/Team Leader
• University of Alberta Hosptial
• email address tfox_at_cha.ab.ca

2
Introduction

• Clinical Pharmacokinetics
• Is the discipline that describes the absorption,
  distribution, metabolism and elimination of the
  drug in patients requiring drug therapy.
• What the body does to the drug.

3
(No Transcript)
4
Introduction

• Pharmacodymics
• The relationship between the concentration of a
  drug and the response obtained in a patient.
• What the drug does to the body.

5
Introduction

• Therapeutic Drug Monitoring
• Measured drug levels to ensure appropriate effect
  or prevent toxic effect
• Assumes a concentration-effect correlation exists
  and is known

6
(No Transcript)
7
Introduction

• Immunosuppresants
• Narrow therapeutic index
• Pharmcodynamic Endpoints are crude

Rejection
Toxicity
Biopsy
Nephrotoxicity Neurotoxicity
8
Pharmacology(Pharmacodynamics)
9
PMN cells,
APC
NK cells,
IL-1
basophils, etc.
IL-2
Tc cell
Th cell
B cell
Cytotoxic Activity
Phagocytosis
Graft Rejection/Destruction
10
Steroids
Cyclosporine, Tacrolimus
APC
IL-1
Aza, MMF, Brequinar, ERL 080
IL-2
CD3,CD25 Abs
Tc cell
Th cell
B cell
Aza, MMF, Brequinar, ERL 080
Sirolimus, RAD
Cytotoxic Activity
Phagocytosis
Graft Rejection/Destruction
11
Calcineurin Inhibitors Cyclosporine Tacrolimus
12
Antiproliferative Agents Sirolimus
13
Cell cycle (Lymphocytes)
Mitosis
G2
G0
Cyclosporine Tacrolimus
G1
S-phase
Sirolimus Everolimus
Mycophenolate Azathioprine, MTX
14
Endothelial cell
Parenchymal cells
Adhesion molecules
CD4
APC
TH
Increased antigen expression
IL-2
MHC II
Cytokine production
Upregulation of adhesion molecules
IFN-g
Upregulation of MHC II molecules
IFN-g
T-cell proliferation
IFN-g
IL-2 IFN-g
IL-1 IL-2
TH
TH
TH
TH
IL-2 IL-4 IL-5 IL-6 IL-10
IL-2 IFN-g IL-4
IFN-g IL-2 TNF-a,-b
Donor cells
IL-2 IFN-g
MHC I
M
TC
NK
B
CD8
Cytotoxic activity
Activation
Activation
P
B
M
TC
Antibody- secreting plasma cells
B-cell proliferation
Complement
Cell-mediated cytotoxicity
Complement
Antibodies
Antibody- dependent cell-mediated cytotoxicity
Lytic damage, vascular occlusion
Inflammatory mediators
15
Summary of Immunosuppresant Pharmacology
16
Pharmacokinetics Cyclosporine, Tacrolimus,
Sirolimus

• High Variable Drug
• Metabolized via Liver - Cyp 3A4
• P-Glycoprotein Substrate/Inhibitor

17
Highly Variable Drugs
1. AUC 2. Cmax 3. Tmax
18
Highly Variable Drugs
AUC0-4
1400
1200
AUC0-12
1000
800
Cyclosporine Concentration (ng/mL)
600
400
200
0
0
2
4
6
8
10
12
Hours Post-Dose
C-0
C-2
Extent and rate of absorption are highly
variable.Patient differences are highlighted in
the absorption phase.
Adapted from Johnston A et al. Transplant Proc.
20003253S-56S.
19
Cyclosporine Pharmacokinetics Differs by Organ
Recipient Type
Dose-Normalised AUC(ngh/mL/mg)
De Novo Renal1
De Novo Liver3
De Novo Heart2
1. Kovarik JM et al. Transplantation.
199458658-663. 2. Cooney GF et al.
Transplantation. 1998301892-1894. 3. Freeman D
et al. Ther Drug Monit. 199517213-216.
20
Highly Variable Drug
21
Highly Variable Drugs
22
Metabolism of Immunosuppresents

• Tacrolimus, Cyclosporine, and Sirolimus are all
  low extraction Drugs
• Clearance of the drug is dependent on enzyme
  efficiency of the liver
• Protein binding is important - Unbound or Free
  Fraction is what can be metabolized.
• Enzyme substrate Cyp - 3A4

23
Cyp 3A4 isoform
24
Protein Binding Sites

• Red Blood Cells Whole Blood levels done for all
  3 drugs
• White Cells T-Lymphocytes
• Lipids HDL, LDL, Apolipoproteins
• Others Albumin, a-Acid Glycoprotein

25
P-Glycoprotein

• Location
• Adrenal Cortex - Cortisol secretion
• Kidney - Brush Border - Urinary Excretion
• Liver - Biliary Excretion
• Small Intestine - Absorption
• Brain - Blood Brain Barrier

26
P-Glycoprotein

• Substrates
• ImmunosuppressantCyclosporine, Tacrolimus,
  Sirolimus,
• Calcium Channel Blockers Verapamil, Diltiazem,
  Nifediine
• Antineoplastics Etoposide, Doxorubicin, Taxol
• Opioids Morphine, Methadone
• Misc Digoxin, Corticosteroids

• Inhibitors
• Cyclosporine, Tacrolimus
• Nifedipine, Diltiazem, Verapamil

27
P-Glycoprotein
28
General TDM Monitoring Strategy

• Starting Dose Loading Dose may be required
• Obtain Trough (C0) Level Determine Desired
  Trough level
• Assess Patients Risk
• Introduction or discontinuation of Cyp-3A4
  inducers or inhibitors
• Introduction or discontinuation of P-GP
  substrates or inhibitors
• Assess blood work - Serum Creatinine, Lipid
  profile, WBC,RBC
• Repeat serum levels based on risk assessment

29
Summary Kinetics
30
Desired Levels
31
Pharmacokinetics Equations

• Current Status Algebra
• Assumes Linearity
• Provides no phsiologically meaningful
  information I.E. Clearance

Cpss Desired
New Dose
Current Dose

Cpss Current
32
Pharmacokinetics Equations
Pharmacokinetics Equations

• Example
• 45 yr old Renal Tx patient
• Current Dose 200mg Twice a day
• Current Level - 105
• Desired Level - 200

200
Cpss Desired
200 380.9
Current Dose

New Dose
105
Cpss Current
Dose 375-400mg
Is this a steady State? Renal Function of
Patient? Cyp 3A4 or P-GP drugs
33
Pharmacokinetics Equations

• Traditional Methods
• Clearance Total Body
• Cltb Ke Vd

Cltb
Ke
or
Vd
34
Pharmacokinetics Equations

• Traditional Methods
• Patient Elimination Rate (Kd)

(S)(F)(Dose)
Cpss min
Vd
ln
Cpss min
Kd
t
35
Pharmacokinetics Equations

• Traditional Methods
• Calculate New Dose

-kdt
(Cpss min)(Vd)(1-e )
Dose
-kdt
(S)(F)(e )
36
New Approaches

• C2 - Monitoring
• Abbreviated AUC
• Absorption Profile

37
AUC0-4 is the Most Variable Region in the Neoral
Pharmacokinetic Profile
Hours Post-Dose
C0
C2
Adapted from Johnston A et al. Transplant Proc.
20003253S-56S.
38
Case

• BG 51 yr old female
• Admitted for Liver tx - Amyloidosis
• Hx of Seizures 6 months earlier
• Meds - Dilantin and Phenobarb
• Started on Sirolimus and Mycophenolate
• What dose of Sirolimus do you recommend?

39
Case

• What do we need to worry about for the dilantin
  or phenobarb?